Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gliadel followed by Avastin and Irinotecan in Recurrent GBM
NCT00735436Phase 2Terminated
- Sponsor
- Duke University
- Start
- Dec 2008
- Primary completion
- Jul 2011
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of carmustine, bevacizumab, irinotecan in glioblastoma (GBM), Gliosarcoma (GS), sponsored by Duke University. Started Dec 2008; status: terminated.
02
Drugs
carmustinebevacizumabirinotecan
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00735436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00735436.